Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis

Below is a press release dated today (3/10/22) from Abivax:

The Quick Basics

Out of the 40 patients who enrolled into the ABX464 maintenance study, 23 patients have now reached the first year of treatment and all achieved at least an ACR201, with 19 and 12 patients achieving ACR50 and ACR70 respectively.

Long-term safety profile (50mg ABX464 once daily + MTX) favorable and consistent with previous observations.

The induction and maintenance results support further clinical development of ABX464 in RA and potentially other rheumatology indications.

The clinical induction and maintenance data in ulcerative colitis and rheumatoid arthritis underpin the potential of ABX464 to address a broad range of chronic inflammatory diseases.

In G7 countries, the market for ulcerative colitis, Crohn’s disease and rheumatoid arthritis is expected to grow to approximately USD 50B in 2026.

The Full Press Release

Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company developing novel therapies that modulate the immune system to treat chronic inflammatory diseases, viral infections, and cancer, today reports promising results from its phase 2a maintenance trial in rheumatoid arthritis (RA) after one year of continued daily treatment with 50mg ABX464.

Continue reading “Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis”

Still’s Disease: Research and Clinical Trials

The following webinar took place back on August 31st, 2021 in honor of Autoinflammatory Awareness Month and Still’s Disease Awareness Day (Sept 7). Nonprofit supporters included International Foundation for Autoimmune & Autoinflammatory Arthritis (AiArthritis), Systemic JIA Foundation, and the Autoinflammatory Alliance. Financial support was provided by Sobi and Avalo Therapeutics.

Current study opportunities

  • Sobi (MAS): Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still’s or SLE (link)
  • Avalo Therapeutics (IL-18): A Study to Evaluate AEVI-007 in Participants With Adult-Onset Still’s Disease (link)

AiArthritis also shared two PDFs in a recent email –

Learn more about AiArthritis’ Still’s Disease work.